Plant ID: NPO13879
Plant Latin Name: Humulus lupulus
Taxonomy Genus: Humulus
Taxonomy Family: Cannabaceae
NCBI TaxonomyDB:
3486
Plant-of-the-World-Online:
n.a.
Anodyne; Antianxiety; Antibacterial; Antiseptic; Antispasmodic; Appetizer; Diuretic; Febrifuge; Galactogogue; Hypnotic; Nervine; Sedative; Stomachic; Tonic
Canada; Turkey; Italy; Czech Republic; Lithuania; India; France; United States; Germany; China; Russia; Spain
TSHR; NPSR1; | |
ALPL; TDP1; PIK3CA; PIK3CB; ALOX12; HSD17B2; HSD17B10; NOX4; NQO2; POLB; | |
ACHE; | |
MET; AXL; FLT3; CDK1; PIM1; KDR; IGF1R; CDK8; AURKB; | |
CA2; CA12; CA9; CA14; CA7; CA4; | |
ESR1; ESR2; | |
NR1H4; | |
TYR; PTGS2; | |
KDM4E; | |
AHR; HIF1A; TP53; NFKB1; | |
FUT7; | |
SLC5A1; SLC5A2; SLC5A4; | |
LMNA; FABP4; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | NQO2 | Quinone reductase 2 | P16083 | CHEMBL3959 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALPL | Alkaline phosphatase, tissue-nonspecific isozyme | P05186 | CHEMBL5979 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | PIK3CA | PI3-kinase p110-alpha subunit | P42336 | CHEMBL4005 |
Enzyme_unclassified | PIK3CB | PI3-kinase p110-beta subunit | P42338 | CHEMBL3145 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | CDK8 | Cell division protein kinase 8 | P49336 | CHEMBL5719 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
SLC superfamily of solute carriers | SLC5A1 | Sodium/glucose cotransporter 1 | P13866 | CHEMBL4979 |
SLC superfamily of solute carriers | SLC5A2 | Sodium/glucose cotransporter 2 | P31639 | CHEMBL3884 |
SLC superfamily of solute carriers | SLC5A4 | Low affinity sodium-glucose cotransporter | Q9NY91 | CHEMBL1770047 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 1.388E-12 | 3.022E-08 | CA12, CA14, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.825E-11 | 2.051E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 1.845E-09 | 2.678E-06 | CA12, CA14, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.757E-09 | 2.678E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, NOX4, PTGS2 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.765E-09 | 4.314E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 9.688E-09 | 6.592E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 4.108E-08 | 2.130E-05 | CA12, CA2, CA4, CA7, CA9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.295E-07 | 1.009E-04 | ALOX12, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 2.701E-07 | 1.153E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.659E-07 | 1.423E-04 | CYP1A2, CYP2C19, CYP3A4 |
MF | GO:0005215; transporter activity | GO:0005412; glucose:sodium symporter activity | 3.659E-07 | 1.423E-04 | SLC5A1, SLC5A2, SLC5A4 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 2.990E-06 | 8.457E-04 | IGF1R, PIK3CA, PIK3CB |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 3.980E-06 | 1.097E-03 | CYP1A2, CYP2C19, CYP3A4 |
BP | GO:0009987; cellular process | GO:0071407; cellular response to organic cyclic compound | 4.114E-06 | 1.120E-03 | ALPL, CYP1A1, CYP1B1, ESR1, FLT3, NFKB1, NOX4, PTGS2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 7.108E-06 | 1.739E-03 | ESR1, ESR2 |
BP | GO:0009987; cellular process | GO:0055082; cellular chemical homeostasis | 8.087E-06 | 1.854E-03 | CA2, CA7, ESR1, HIF1A, NOX4, NPSR1, NR1H4, PIK3CA, PIK3CB, TP53 |
BP | GO:0050896; response to stimulus | GO:0032496; response to lipopolysaccharide | 8.910E-06 | 1.970E-03 | ALPL, AXL, CYP1A1, CYP1A2, NFKB1, NR1H4, PTGS2 |
BP | GO:0008152; metabolic process | GO:0008610; lipid biosynthetic process | 1.486E-05 | 2.839E-03 | ACHE, ALOX12, CYP19A1, CYP1A1, CYP3A4, HSD17B2, PIK3CA, PIK3CB, PTGS2 |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 2.129E-05 | 3.747E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 2.129E-05 | 3.747E-03 | CYP1A1, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 2.365E-05 | 4.023E-03 | CYP1A1, POLB, TP53 |
BP | Unclassified; | GO:0035428; hexose transmembrane transport | 2.733E-05 | 4.413E-03 | SLC5A1, SLC5A2, SLC5A4 |
BP | GO:0051179; localization | GO:1904659; glucose transmembrane transport | 2.733E-05 | 4.413E-03 | SLC5A1, SLC5A2, SLC5A4 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 3.137E-05 | 4.950E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.196E-05 | 5.971E-03 | AXL, KDR, PIK3CA, PIK3CB |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.250E-05 | 5.971E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 4.250E-05 | 5.971E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 4.250E-05 | 5.971E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0006706; steroid catabolic process | 4.580E-05 | 6.311E-03 | CYP19A1, CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0031328; positive regulation of cellular biosynthetic process | 4.719E-05 | 6.422E-03 | AHR, AURKB, CDK1, CDK8, ESR1, ESR2, HIF1A, IGF1R, MET, NFKB1, NOX4, NR1H4, PTGS2, TP53, TSHR |
BP | GO:0032501; multicellular organismal process | GO:0010575; positive regulation of vascular endothelial growth factor production | 5.142E-05 | 6.869E-03 | CYP1B1, HIF1A, PTGS2 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 5.239E-05 | 6.956E-03 | CA12, CA2, CA4, CA7, CA9, ESR1, ESR2, NQO2, NR1H4, TP53 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 5.449E-05 | 7.191E-03 | AXL, MET, NOX4, PIK3CA, PIK3CB |
BP | GO:0008152; metabolic process | GO:0008209; androgen metabolic process | 5.748E-05 | 7.436E-03 | CYP19A1, CYP3A4, ESR1 |
BP | GO:0032502; developmental process | GO:0045766; positive regulation of angiogenesis | 5.799E-05 | 7.436E-03 | ALOX12, CYP1B1, HIF1A, KDR, PTGS2 |
BP | GO:0050896; response to stimulus | GO:0009725; response to hormone | 5.936E-05 | 7.559E-03 | ALPL, CA2, CA9, CYP1A2, ESR1, FLT3, NFKB1, PTGS2, TSHR |
BP | GO:0008152; metabolic process | GO:0006367; transcription initiation from RNA polymerase II promoter | 6.952E-05 | 8.457E-03 | CDK1, CDK8, ESR1, ESR2, NR1H4 |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 7.071E-05 | 8.507E-03 | CYP1A1, CYP3A4 |
MF | GO:0005488; binding | GO:0042802; identical protein binding | 7.249E-05 | 8.673E-03 | ACHE, ESR1, ESR2, FLT3, IGF1R, KDR, MET, NFKB1, NQO2, PTGS2, SMN1, SMN2, TP53, TYR |
MF | GO:0005488; binding | GO:0005496; steroid binding | 8.424E-05 | 9.757E-03 | CYP3A4, ESR1, ESR2, NR1H4 |
BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 8.584E-05 | 9.796E-03 | IGF1R, NFKB1, NOX4, NR1H4, PTGS2, TP53, TSHR |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 8.637E-05 | 9.796E-03 | AHR, HIF1A, KDR |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.776E-12 | 4.164E-10 | CA12, CA2, CA4, CA7, CA9, CA14 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 3.339E-09 | 2.504E-07 | HSD17B2, CYP1A1, CYP1B1, PTGS2, CYP19A1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 5.036E-08 | 1.511E-06 | PIK3CA, KDR, PIK3CB, TP53, HIF1A, ESR1, MET, IGF1R |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 8.372E-09 | 4.186E-07 | CYP1A2, HSD17B2, CYP1A1, CYP1B1, CYP3A4, CYP19A1 |
09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 2.028E-08 | 7.604E-07 | PIK3CA, FLT3, PIK3CB, TP53, MET, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 7.561E-07 | 1.260E-05 | PIK3CA, FLT3, PIK3CB, PTGS2, HIF1A, MET, TP53, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 3.687E-07 | 6.914E-06 | PIK3CA, FLT3, PIM1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 3.370E-07 | 6.914E-06 | FABP4, PIK3CA, PIK3CB, PTGS2, TSHR |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 6.908E-08 | 1.727E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
09160 Human Diseases | 09161 Cancers | hsa05218 | Melanoma | 1.116E-06 | 1.631E-05 | PIK3CA, PIK3CB, TP53, MET, IGF1R |
09150 Organismal Systems | 09152 Endocrine system | hsa04917 | Prolactin signaling pathway | 1.196E-06 | 1.631E-05 | PIK3CA, PIK3CB, ESR1, NFKB1, ESR2 |
09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 3.433E-06 | 3.961E-05 | PIK3CA, PIK3CB, TP53, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05222 | Small cell lung cancer | 2.897E-06 | 3.622E-05 | PIK3CA, PIK3CB, PTGS2, TP53, NFKB1 |
09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 4.496E-06 | 4.817E-05 | PIK3CA, PIK3CB, TP53, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05206 | MicroRNAs in cancer | 1.120E-05 | 1.050E-04 | PIK3CA, PIM1, CYP1B1, PTGS2, TP53, MET, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 7.045E-06 | 7.045E-05 | PIK3CA, PIK3CB, HIF1A, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.482E-05 | 1.235E-04 | POLB, PIK3CA, CDK1, PIK3CB, TP53, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 1.367E-05 | 1.206E-04 | PIK3CA, PIK3CB, TP53, ESR1, HIF1A |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04151 | PI3K-Akt signaling pathway | 2.726E-05 | 1.704E-04 | PIK3CA, KDR, PIK3CB, TP53, MET, NFKB1, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04014 | Ras signaling pathway | 2.634E-05 | 1.704E-04 | PIK3CA, KDR, PIK3CB, MET, NFKB1, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 2.446E-05 | 1.704E-04 | PIK3CA, PIK3CB, TP53, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04370 | VEGF signaling pathway | 1.900E-05 | 1.500E-04 | PIK3CA, KDR, PIK3CB, PTGS2 |
09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.121E-05 | 1.873E-04 | PIK3CA, LMNA, PIK3CB, TP53, NFKB1 |
09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 2.599E-05 | 1.704E-04 | PIK3CA, PIK3CB, TP53, NFKB1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 6.182E-05 | 3.091E-04 | FUT7, HSD17B2, CYP1A2, CYP1A1, ALPL, ALOX12, PTGS2, CYP2C19, CYP3A4, TYR, CYP19A1, HSD17B10 |
09160 Human Diseases | 09161 Cancers | hsa05211 | Renal cell carcinoma | 2.599E-05 | 1.704E-04 | PIK3CA, PIK3CB, MET, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 3.873E-05 | 2.075E-04 | PIK3CA, PIK3CB, TP53, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.377E-04 | 6.075E-04 | PIK3CA, PIM1, PIK3CB, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04914 | Progesterone-mediated oocyte maturation | 1.225E-04 | 5.743E-04 | PIK3CA, CDK1, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05202 | Transcriptional misregulation in cancer | 1.031E-04 | 4.987E-04 | FLT3, TP53, MET, NFKB1, IGF1R |
09150 Organismal Systems | 09154 Digestive system | hsa04976 | Bile secretion | 3.471E-05 | 2.002E-04 | CA2, NR1H4, SLC5A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.873E-05 | 2.075E-04 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09160 Human Diseases | 09167 Infectious diseases | hsa05169 | Epstein-Barr virus infection | 1.768E-04 | 7.167E-04 | PIK3CA, CDK1, PIK3CB, TP53, NFKB1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 1.274E-04 | 5.792E-04 | PIK3CA, PIK3CB, ESR1, ESR2 |
09140 Cellular Processes | 09144 Cellular community - eukaryotes | hsa04510 | Focal adhesion | 1.768E-04 | 7.167E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04015 | Rap1 signaling pathway | 2.165E-04 | 8.167E-04 | PIK3CA, KDR, PIK3CB, MET, IGF1R |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04668 | TNF signaling pathway | 1.914E-04 | 7.554E-04 | PIK3CA, PIK3CB, PTGS2, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04722 | Neurotrophin signaling pathway | 2.671E-04 | 9.540E-04 | PIK3CA, PIK3CB, TP53, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.671E-04 | 9.540E-04 | PIK3CA, PIK3CB, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05166 | HTLV-I infection | 5.445E-04 | 1.655E-03 | POLB, PIK3CA, PIK3CB, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05160 | Hepatitis C | 3.952E-04 | 1.347E-03 | PIK3CA, PIK3CB, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05162 | Measles | 4.300E-04 | 1.402E-03 | PIK3CA, PIK3CB, TP53, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 5.620E-04 | 1.655E-03 | PIK3CA, PIK3CB, TP53, NFKB1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.773E-03 | 4.585E-03 | PIK3CA, PIK3CB, NFKB1, TSHR |
09150 Organismal Systems | 09157 Sensory system | hsa04750 | Inflammatory mediator regulation of TRP channels | 2.119E-03 | 5.386E-03 | PIK3CA, ALOX12, PIK3CB |
09160 Human Diseases | 09161 Cancers | hsa05223 | Non-small cell lung cancer | 4.169E-04 | 1.390E-03 | PIK3CA, PIK3CB, TP53 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 5.109E-04 | 1.631E-03 | PIK3CA, PIK3CB, HIF1A |
09160 Human Diseases | 09161 Cancers | hsa05213 | Endometrial cancer | 3.348E-04 | 1.168E-03 | PIK3CA, PIK3CB, TP53 |
09160 Human Diseases | 09161 Cancers | hsa05231 | Choline metabolism in cancer | 2.309E-03 | 5.677E-03 | PIK3CA, PIK3CB, HIF1A |
09160 Human Diseases | 09167 Infectious diseases | hsa05146 | Amoebiasis | 2.244E-03 | 5.610E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04662 | B cell receptor signaling pathway | 9.068E-04 | 2.473E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09156 Nervous system | hsa04725 | Cholinergic synapse | 3.017E-03 | 6.858E-03 | ACHE, PIK3CA, PIK3CB |
09150 Organismal Systems | 09151 Immune system | hsa04660 | T cell receptor signaling pathway | 2.509E-03 | 5.974E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09151 Immune system | hsa04620 | Toll-like receptor signaling pathway | 2.648E-03 | 6.207E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04931 | Insulin resistance | 2.866E-03 | 6.614E-03 | PIK3CA, PIK3CB, NFKB1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05142 | Chagas disease (American trypanosomiasis) | 2.509E-03 | 5.974E-03 | PIK3CA, PIK3CB, NFKB1 |
09150 Organismal Systems | 09149 Aging | hsa04213 | Longevity regulating pathway - multiple species | 6.175E-04 | 1.781E-03 | PIK3CA, PIK3CB, IGF1R |
09160 Human Diseases | 09161 Cancers | hsa05210 | Colorectal cancer | 5.626E-04 | 1.655E-03 | PIK3CA, PIK3CB, TP53 |
09160 Human Diseases | 09167 Infectious diseases | hsa05100 | Bacterial invasion of epithelial cells | 1.099E-03 | 2.944E-03 | PIK3CA, PIK3CB, MET |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 3.095E-03 | 6.929E-03 | ALOX12, CYP2C19, PTGS2 |
09160 Human Diseases | 09167 Infectious diseases | hsa05145 | Toxoplasmosis | 3.585E-03 | 7.908E-03 | PIK3CA, PIK3CB, NFKB1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 1.530E-04 | 6.558E-04 | CYP1A2, CYP1A1, CYP1B1 |
09130 Environmental Information Processing | 09132 Signal transduction | hsa04152 | AMPK signaling pathway | 4.120E-03 | 8.956E-03 | PIK3CA, PIK3CB, IGF1R |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 7.695E-04 | 2.138E-03 | CYP1A2, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09154 Digestive system | hsa04973 | Carbohydrate digestion and absorption | 2.178E-04 | 8.167E-04 | PIK3CA, PIK3CB, SLC5A1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 6.462E-04 | 1.829E-03 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 5.626E-04 | 1.655E-03 | ALOX12, CYP2C19, PTGS2 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.775E-05 | 2.987E-04 | CYP1A2, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09155 Excretory system | hsa04960 | Aldosterone-regulated sodium reabsorption | 4.620E-03 | 9.900E-03 | PIK3CA, PIK3CB |
09150 Organismal Systems | 09155 Excretory system | hsa04964 | Proximal tubule bicarbonate reclamation | 1.620E-03 | 4.263E-03 | CA2, CA4 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | SLC5A4; SLC5A1; SLC5A2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | MET; AURKB; IGF1R; PIK3CA; KDR; FLT3; HIF1A; PIK3CB; TP53; CA9; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; CA2; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R; |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | IGF1R; KDR; FLT3; TP53; |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; ALPL; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; CDK1; IGF1R; ACHE; PTGS2; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | TYR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; FLT3; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKB; FLT3; TP53; |
C00-D49: Neoplasms | Multiple myeloma | C90 | IGF1R; AHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | NFKB1; PTGS2; SLC5A4; SLC5A1; SLC5A2; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | SLC5A2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53; |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | SLC5A4; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; TYR; |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; TP53; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; KDR; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
NA: NA | HIV infections | NA | AHR; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; IGF1R; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PIK3CA; TP53; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; FLT3; |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET; |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | PIK3CB; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Genetic disease | Q00-Q99 | ALPL; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | CYP3A4; ACHE; |
A00-B99: Certain infectious and parasitic diseases | Anthelmintic | B89 | ALPL; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; PIM1; MET; CDK1; IGF1R; PIK3CA; KDR; NFKB1; FLT3; ACHE; HIF1A; PTGS2; PIK3CB; NQO2; TP53; CA9; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; |
NA: NA | GIST | NA | FLT3; |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3; |
C00-D49: Neoplasms | Glioma | C71 | KDR; |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3; |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3; |
C00-D49: Neoplasms | CLL | NA | FLT3; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; CYP19A1; |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; PTGS2; |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; |
C00-D49: Neoplasms | AML | NA | KDR; FLT3; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; PTGS2; |
NA: NA | Edema | NA | CA2; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; NPSR1; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; TYR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; IGF1R; KDR; AXL; PTGS2; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | FLT3; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; CDK1; IGF1R; KDR; FLT3; NQO2; CYP19A1; CA9; |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3; |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; CA9; |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET; SLC5A2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; TP53; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; FLT3; PTGS2; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |